Safety of Extended-Interval Dosing Strategy of Immune Checkpoint Inhibitors for Advanced NSCLC

[1]  R. Elisei,et al.  Chylous effusions in advanced medullary thyroid cancer patients treated with selpercatinib. , 2022, European Journal of Endocrinology.

[2]  S. Digumarthy,et al.  Brief Report: Chylothorax and Chylous Ascites During RET Tyrosine Kinase Inhibitor Therapy. , 2022, Journal of Thoracic Oncology.

[3]  Y. Ohe,et al.  Safety implications of switching pembrolizumab dosage from 200 mg Q3W to 400 mg Q6W in patients with advanced non-small-cell lung cancer. , 2022, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[4]  F. Bensch,et al.  Safety and Efficacy of Extended Interval Dosing for Immune Checkpoint Inhibitors in Non–Small Cell Lung Cancer During the COVID-19 Pandemic , 2021, Clinical Lung Cancer.

[5]  N. Yamamoto,et al.  Pembrolizumab plus chemotherapy-induced pneumonitis in chemo-naïve patients with non-squamous non-small cell lung cancer: A multicentre, retrospective cohort study. , 2021, European journal of cancer.

[6]  H. Léna,et al.  179P Efficacy and safety of extended-interval dosing strategy of immune checkpoint inhibitors during the COVID-19 outbreak: Experience from a single center , 2021, Journal of Thoracic Oncology.

[7]  M. Itkin,et al.  An Algorithmic Approach to Minimally Invasive Management of Nontraumatic Chylothorax , 2020, Seminars in Interventional Radiology.

[8]  S. Jabbour,et al.  ALK inhibitors and checkpoint blockade: a cautionary tale of mixing oil with water? , 2018, Journal of thoracic disease.

[9]  F. Maldonado,et al.  Medical and Surgical Management of Chylothorax and Associated Outcomes , 2010, The American journal of the medical sciences.